TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30326880

Group type: EXPERIMENTAL
Intervention: Regular partners
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Casual partners
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Both types of partners
Number of subjects: 1057
Study: 26846550

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.5 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24705757

Group type: EXPERIMENTAL
Intervention: Raw vegetable meals
Number of subjects: 153

Group type: COMPARATOR
Intervention: Boiled vegetable meals
Number of subjects: 153
Study: 22848033

Group type: EXPERIMENTAL
Intervention: Gadoterate (0.1 mmol/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gadoterate
Number of subjects: 20
Study: 20234301

Group type: EXPERIMENTAL
Intervention: ARB plus azelnidipine (AZ group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: ARB plus trichlormethiazide (TCM group)
Number of subjects: 37
Study: 19029270

Group type: EXPERIMENTAL
Intervention: 40,000 IU of epoetin alpha (EPOalpha)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard medical and surgical treatment
Number of subjects: 67
Study: 15836934

Group type: EXPERIMENTAL
Intervention: Stabilisation exercises (S&G group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: General exercise only (G group)
Number of subjects: 55
Study: 12207568

Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/day in hypercholesterolaemic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg/day in hypercholesterolaemic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Policosanol (20 and 40 mg/day)
Number of subjects: 0
Study: 11235577

Group type: EXPERIMENTAL
Intervention: Zeng Sheng-ping (ZSP), 8 tablets, twice a day for 6 months
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Zeng Sheng-ping (ZSP)
Number of subjects: 449
Study: 8670315

Group type: EXPERIMENTAL
Intervention: Chimeric anti-TNF alpha antibody cA2 (1 or 10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chimeric anti-TNF alpha antibody cA2
Number of subjects: 0
Study: 1984989

Group type: EXPERIMENTAL
Intervention: Albuterol 270 micrograms (three puffs) from a metered dose inhaler
Number of subjects: 18

Group type: COMPARATOR
Intervention: Albuterol 2.5 mg from a saline solution nebulized with an updraft inhaler
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both delivery methods
Number of subjects: 18
Study: 6135076

Group type: EXPERIMENTAL
Intervention: Intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Volume repletion
Number of subjects: 30
Study: 31492475

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 720

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 720
Study: 28905830

Group type: EXPERIMENTAL
Intervention: Recession and resection (R&R)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Recession and plication (R&P)
Number of subjects: 40
Study: 26076204

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic group psychotherapy (LTG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-term psychodynamic group psychotherapy (STG)
Number of subjects: 0
Study: 24451697

Group type: EXPERIMENTAL
Intervention: Inhaled 1600 μg salbutamol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 16
Study: 22130425

Group type: COMPARATOR
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sublingual Immunotherapy followed by Oral Immunotherapy (SLIT/OITB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral Immunotherapy (OITA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OITB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall reaction rate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Titrated CM skin prick test results
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CD63 and CD203c expression
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CM-specific IgG(4) levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CM-specific IgE and spontaneous histamine release values
Number of subjects: 30
Study: 20223648

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.0625% bupivacaine
Number of subjects: 0
Study: 17646413

Group type: COMPARATOR
Intervention: Voriconazole 200 mg BID for 3 days, followed by ritonavir 400 mg BID for 10 days, then voriconazole 200 mg BID with ritonavir for 10 days (Study A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Voriconazole 200 mg BID for 3 days, followed by ritonavir 100 mg BID for 10 days, then voriconazole 200 mg BID with ritonavir for 10 days (Study B)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Voriconazole coadministered with high-dose ritonavir
Number of subjects: 51

Group type: COMPARATOR
Intervention: Voriconazole coadministered with low-dose ritonavir
Number of subjects: 51

Group type: COMPARATOR
Intervention: Combination therapy of voriconazole and ritonavir
Number of subjects: 51
Study: 15094733

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% added to timolol maleate 0.5%
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unoprostone 0.15% added to timolol maleate 0.5%
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unoprostone 0.15%
Number of subjects: 33
Study: 12409716

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy with cyproterone acetate (CPA), 300 mg/day for 12 weeks
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy with cyproterone acetate (CPA)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Surgery alone (control)
Number of subjects: 192
Study: 9793616

Group type: EXPERIMENTAL
Intervention: Standard, slow-release horse chestnut seed extract (HCSE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast-release test preparation (Noricaven novo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both products (HCSE and Noricaven novo)
Number of subjects: 0
Study: 7633141

Group type: EXPERIMENTAL
Intervention: NaHCO3 or NaCl (2 mmol/kg/day each) for 7 days
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no specific therapy)
Number of subjects: 149
Study: 3720570

Group type: EXPERIMENTAL
Intervention: Intervention group (10,000 men) received dietary advice, smoking cessation advice, and antihypertensive treatment.
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Control group (20,000 men) received health examinations and general health advice.
Number of subjects: 30000
Study: 31711275

Group type: EXPERIMENTAL
Intervention: e-health self-control training during inpatient MOT (intensive phase)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: e-health self-control training during outpatient aftercare (booster phase)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low adherence group
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: End of inpatient MOT and high weight status
Number of subjects: 68
Study: 29482683

Group type: EXPERIMENTAL
Intervention: Biodentine plus Ketac Molar
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NuSmile NeoMTA plus Tempit LC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NeoMTA Plus plus Fuji IX
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MTA Angelus plus IRM capsule
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MTA Flow plus IRM powder and liquid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Solo bioactive cement pulp chamber filling (protocol B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 30
Study: 27439408

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 60
Study: 24667518

Group type: EXPERIMENTAL
Intervention: Formal mentoring curriculum
Number of subjects: 16
Study: 22615152

Group type: EXPERIMENTAL
Intervention: Medial capsule reefing (Group A)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Medial patellar retinaculum plasty (Group B)
Number of subjects: 78
Study: 20227675

Group type: EXPERIMENTAL
Intervention: Femtosecond laser flap creation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mechanical microkeratome flap creation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 21
Study: 18164457

Group type: EXPERIMENTAL
Intervention: Intradiscal electrothermal therapy
Number of subjects: 0
Study: 19931756

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hypertonic lactate saline (HLS) solution
Number of subjects: 110
Study: 15675479

Group type: EXPERIMENTAL
Intervention: High dose mitomycin and epirubicin with caval chemofiltration (CF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low doses of mitomycin and epirubicin
Number of subjects: 42
Study: 11372943

Group type: EXPERIMENTAL
Intervention: Medoff sliding plate (MSP)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Dynamic hip screw with trochanteric stabilizing plate (DHS/TSP)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Dynamic condylar screw (DCS)
Number of subjects: 569

Group type: COMPARATOR
Intervention: All groups (MSP vs DHS, DHS/TSP, DCS)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: MSP
Number of subjects: 569

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 569
Study: 9248749

Group type: EXPERIMENTAL
Intervention: Gentamicin 3 mg/kg i.v. bolus and norfloxacin 400 mg twice daily orally from the start
Number of subjects: 158

Group type: COMPARATOR
Intervention: Cefotaxime 2 g i.v. twice daily for at least two days followed by norfloxacin 400 mg twice daily orally
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Gentamicin with early oral therapy
Number of subjects: 158
Study: 8321793

Group type: EXPERIMENTAL
Intervention: Imprint cytology
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 239

Group type: COMPARATOR
Intervention: CLO-test
Number of subjects: 239

Group type: COMPARATOR
Intervention: CLO-test in patients receiving colloidal bismuth subcitrate
Number of subjects: 239
Study: 3541564

Group type: EXPERIMENTAL
Intervention: Manufactured snacks (chocolate‐coated candy bar; cola drink with crisps)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole-food snacks (raisins and peanuts; bananas and peanuts)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Banana-peanut snack
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Manufactured snacks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole-food snacks
Number of subjects: 10
Study: 4593555

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (aspirin) - single daily dose
Number of subjects: 1239
Study: 30773798

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 3555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3555
Study: 30166087

Group type: EXPERIMENTAL
Intervention: Combined sarcoidosis and IPF (CSIPF)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lone-IPF
Number of subjects: 78

Group type: COMPARATOR
Intervention: Pulmonary sarcoidosis
Number of subjects: 78
Study: 26833624

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray for 14 days
Number of subjects: 80
Study: 22886317

Group type: EXPERIMENTAL
Intervention: Inter-organizational collaboration
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care
Number of subjects: 38
Study: 22265994

Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 mg intramuscular on days 1, 29, and 57, plus daily immediate-release octreotide 600 μg per day and methylprednisolone on days 1 to 6.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo with methylprednisolone instead of octreotide.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Octreotide LAR in patients with baseline Karnofsky score >= 50.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo in patients with baseline Karnofsky score >= 50.
Number of subjects: 64
Study: 21069110

Group type: EXPERIMENTAL
Intervention: Hybrid composite (Filtek Z100 Universal Restorative)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nanocomposite (Filtek Z350)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ormocer (Voco Admira)
Number of subjects: 90
Study: 18210355

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED) for lumbar disc herniation with bony fragment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Microendoscopic discectomy (MED) for lumbar disc herniation without bony fragment (Control group)
Number of subjects: 18
Study: 15336334

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 187

Group type: COMPARATOR
Intervention: Women
Number of subjects: 187
Study: 11673215

Group type: EXPERIMENTAL
Intervention: Nasal-mask NPPV
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-NPPV
Number of subjects: 48
Study: 9843006

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% shampoo (3-day application)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% shampoo (1-day application)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo shampoo
Number of subjects: 312
Study: 7735003

Group type: EXPERIMENTAL
Intervention: Counseling with stages-of-change model
Number of subjects: 93

Group type: COMPARATOR
Intervention: Reminder reading 'Ask your patients to stop smoking'
Number of subjects: 93

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 93
Study: 2785982

Group type: EXPERIMENTAL
Intervention: Speech processor with electrical stimulation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Processor delivering subthreshold current for 2 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo trial
Number of subjects: 38
Study: 29567399

Group type: COMPARATOR
Intervention: BI 409306 25 mg, 50 mg, 100 mg, placebo once daily (OD) for 14 days (Trial 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BI 409306 25 mg, 50 mg, placebo OD for 14 days (Trial 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BI 409306 25 mg, 50 mg, 100 mg, placebo single doses (SD) (Trial 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BI 409306 100 mg SD or placebo for Chinese poor metabolisers (PM) (Trial 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BI 409306 100 mg OD for 7 days after a 48-hour washout period (Japanese PM, Trial 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 409306 (various doses)
Number of subjects: 0
Study: 28778393

Group type: EXPERIMENTAL
Intervention: 4.4 g of fish oil
Number of subjects: 80
Study: 26297574

Group type: EXPERIMENTAL
Intervention: Topical clobetasol 0.05% ointment applied daily for 14 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control petrolatum ointment applied daily for 14 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topical clobetasol 0.05% ointment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control petrolatum ointment
Number of subjects: 15
Study: 22781309

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (60% VO2max)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High intensity exercise (80% VO2max)
Number of subjects: 35
Study: 21635612

Group type: EXPERIMENTAL
Intervention: β-blockade during exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: β-blockade during recovery
Number of subjects: 10

Group type: COMPARATOR
Intervention: β-blockade during exercise in normal subjects
Number of subjects: 10

Group type: COMPARATOR
Intervention: β-blockade during recovery in normal subjects
Number of subjects: 10
Study: 18439469

Group type: EXPERIMENTAL
Intervention: Internal nasal dilation stent (INDS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: External nasal dilator (END)
Number of subjects: 23
Study: 16542392

Group type: EXPERIMENTAL
Intervention: Common genetic variants of HDL-C-related genes
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Common genetic variants of HDL-C-related genes with covariates smoking and body mass index
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Common genetic variants of HDL-C-related genes with covariates and 10 two-way interactions
Number of subjects: 546
Study: 12022154

Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg for 3 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 43
Study: 11910595

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg daily) for 8 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined hormone therapy (up to 1.25 mg of conjugated equine estrogens plus 5 mg of medroxyprogesterone acetate daily) for 8 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and hormone therapy (same dosages as above)
Number of subjects: 23
Study: 8944104

Group type: EXPERIMENTAL
Intervention: Probing (intervention)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Spontaneous resolution (control)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Probing at 12-14 months (intervention)
Number of subjects: 95
Study: 1783919

Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (3,4-DAP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (3,4-DAP) in a double blind crossover trial
Number of subjects: 16
Study: 6814669

Group type: EXPERIMENTAL
Intervention: Synthetic analogue of enkephalin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline (0.5 ml)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg IV)
Number of subjects: 5
Study: 31303007

Group type: EXPERIMENTAL
Intervention: Intuitive Movement Reembodiment (IMR) program, 10 weekly sessions
Number of subjects: 22
Study: 31411779

Group type: COMPARATOR
Intervention: Randomised treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediator levels
Number of subjects: 0
Study: 27893884

Group type: EXPERIMENTAL
Intervention: GOC video decision aid plus structured discussion
Number of subjects: 302

Group type: COMPARATOR
Intervention: Attention control with informational video and usual care planning
Number of subjects: 302
Study: 25545238

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan plus hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irbesartan alone
Number of subjects: 0
Study: 24380742

Group type: EXPERIMENTAL
Intervention: Universal cystoscopy at incontinence surgery
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Retropubic urethropexy and retropubic midurethral sling (MUS) procedures
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Autologous pubovaginal sling procedures
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Transobturator MUS
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Trocar perforation
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Increasing age, vaginal deliveries, and blood loss
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Age and smoking history
Number of subjects: 1830
Study: 22958651

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 214

Group type: COMPARATOR
Intervention: High-definition white-light endoscopy (WLE)
Number of subjects: 214
Study: 19183227

Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 17409390

Group type: EXPERIMENTAL
Intervention: Physiological Cost Index
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oxygen cost
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 27
Study: 15048065

Group type: EXPERIMENTAL
Intervention: CD38 expression threshold >=7%
Number of subjects: 289

Group type: COMPARATOR
Intervention: CD38 expression threshold >=30%
Number of subjects: 289

Group type: COMPARATOR
Intervention: Intermediate values between 7% and 29% CD38 positive cells
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: CD38 expression threshold <7%
Number of subjects: 289

Group type: COMPARATOR
Intervention: CD38 expression threshold >=30% and >=7%
Number of subjects: 289
Study: 11437863

Group type: EXPERIMENTAL
Intervention: Optimal insole support
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional footwear
Number of subjects: 81
Study: 9149578

Group type: EXPERIMENTAL
Intervention: Salmeterol, 100 micrograms twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7956717

Group type: EXPERIMENTAL
Intervention: etofibrate
Number of subjects: 50

Group type: COMPARATOR
Intervention: gemfibrozil
Number of subjects: 50
Study: 2439000

Group type: EXPERIMENTAL
Intervention: Intrathecal anti-tetanus serum (ATS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intramuscular anti-tetanus serum (ATS)
Number of subjects: 66
Study: 31282290

Group type: EXPERIMENTAL
Intervention: Differential methylation at 227 CpGs associated with expression of 40 nearby miRNAs (cis-miR-eQTMs) at FDR<0.01
Number of subjects: 3565

Group type: EXPERIMENTAL
Intervention: Bidirectional Mendelian randomization (MR) analysis
Number of subjects: 3565

Group type: EXPERIMENTAL
Intervention: Integration of genetic variants in joint analyses
Number of subjects: 3565

Group type: EXPERIMENTAL
Intervention: Two-step MR analysis
Number of subjects: 3565
Study: 31697272

Group type: EXPERIMENTAL
Intervention: TEE in hypnosis (n = 23)
Number of subjects: 50

Group type: COMPARATOR
Intervention: TEE in sedation (n = 27)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups during TEE
Number of subjects: 50
Study: 27166320

Group type: EXPERIMENTAL
Intervention: Rheumatologic disorders
Number of subjects: 4605

Group type: EXPERIMENTAL
Intervention: Rheumatologic disorders (STEMI subgroup)
Number of subjects: 4605

Group type: EXPERIMENTAL
Intervention: Rheumatologic disorders (all patients)
Number of subjects: 4605